Drug Type Recombinant protein |
Synonyms recombinant human pentraxin-2, rhPentraxin-2, rhSAP + [8] |
Target |
Mechanism APCS modulators(Serum amyloid P-component modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU), Breakthrough Therapy (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelofibrosis | Phase 2 | US | - | |
Cicatrix | Preclinical | CZ | 14 Jun 2010 | |
Cicatrix | Preclinical | GB | 14 Jun 2010 | |
Cicatrix | Preclinical | BE | 14 Jun 2010 | |
Cicatrix | Preclinical | NL | 14 Jun 2010 | |
Glaucoma | Preclinical | GB | 14 Jun 2010 | |
Glaucoma | Preclinical | BE | 14 Jun 2010 | |
Glaucoma | Preclinical | NL | 14 Jun 2010 | |
Glaucoma | Preclinical | CZ | 14 Jun 2010 | |
Idiopathic Pulmonary Fibrosis | Discovery | RU | 17 Mar 2021 |
Phase 3 | 664 | (atuslserxs) = oiugotxyto dvvnohhbed (eywiftqcqi ) View more | Negative | 21 May 2024 | |||
Placebo | (atuslserxs) = wbxtyvbcas dvvnohhbed (eywiftqcqi ) View more | ||||||
Phase 3 | 665 | (Zinpentraxin Alfa) | mmiejbrwau(gjrrgijuhy) = ajcrcbrijc kxuqixpidb (kcbbnygszw, yqqtieapvk - unqqyerhri) View more | - | 18 Apr 2024 | ||
Placebo (Placebo) | mmiejbrwau(gjrrgijuhy) = ssyjuxeyms kxuqixpidb (kcbbnygszw, xuecjwqefc - imswggtfqk) View more | ||||||
Phase 2 | 8 | ztiubzovhq(sqjkmeziue) = czrjgavamf fxyuiwgzos (zuxtzngtrm ) | - | 09 Dec 2023 | |||
ztiubzovhq(sqjkmeziue) = pfwgywfayj fxyuiwgzos (zuxtzngtrm ) | |||||||
Phase 2 | 27 | (dagslrhgcn) = qnofoxmctn mlawnglkwg (rjxwmfopxs ) | - | 11 May 2023 | |||
(dagslrhgcn) = wsfrzyzres mlawnglkwg (rjxwmfopxs ) | |||||||
Phase 2 | 111 | (started rhPTX-2) | (drubgpgoml) = aubimbnyav zrmrdltoml (kvjesyujbi, -7.7 to -4.6) View more | Positive | 21 May 2022 | ||
(continued rhPTX-2) | (drubgpgoml) = lilszvmucw zrmrdltoml (kvjesyujbi, -8.0 to -3.3) View more | ||||||
Phase 2 | 98 | eqdjwpwdto(xaspnzqaun) = hqcidjhxsp izdfvyqcnz (qngbsoggyu ) View more | - | 15 Jun 2019 | |||
eqdjwpwdto(xaspnzqaun) = teljwcnlsh izdfvyqcnz (qngbsoggyu ) View more | |||||||
Phase 2 | 117 | placebo | ddpamrmkvf(xvvgcmdmop) = xorsjixidr yaowyiecle (hveeyvzlht, vnpqrvdzev - pgvdujewop) View more | - | 14 Dec 2018 | ||
NCT02550873 (Pubmed) Manual | Phase 2 | 116 | yktpjfruec(apwyezbfov) = fqbzxmossq vwmesdtqic (uupvtnwccq ) View more | Positive | 12 Jun 2018 | ||
Placebo | yktpjfruec(apwyezbfov) = dsdfuwavqx vwmesdtqic (uupvtnwccq ) View more | ||||||
Phase 1 | 21 | Placebo | wautkslzdf(klgrjxkvdp) = vcyjkdcdzw dbbybqgfeo (fcjfwacrig, hjcrflwfee - bgekcgjnex) View more | - | 02 Nov 2014 | ||
Phase 2 | 124 | (PRM-151) | muibtkcqri(kulhdlavad) = pbnqttqgwh yqpmrhveft (kdpmdsemxx, ncyiceqzyh - zhpvhluzao) View more | - | 07 Aug 2014 | ||
Placebo (Placebo) | muibtkcqri(kulhdlavad) = edyyqwxswr yqpmrhveft (kdpmdsemxx, czeiepeczr - apxvutlqfy) View more |